References of "Krzesinski, Jean-Marie"
     in
Bookmark and Share    
Full Text
See detailLes nouvelles directives du contrôle de l'HTA
Krzesinski, Jean-Marie ULg

Conference (2014, May 17)

Successivement au mois de juin 2013 et fin de l’année 2013 sont apparues trois recommandations sur la prise en charge de l’hypertension artérielle. La première relevait de la Société Européenne ... [more ▼]

Successivement au mois de juin 2013 et fin de l’année 2013 sont apparues trois recommandations sur la prise en charge de l’hypertension artérielle. La première relevait de la Société Européenne d’Hypertension et les deux autres de sociétés américaines et internationales. Ces directives accordaient toutes une importante place aux mesures de pression artérielle (PA) en dehors du cabinet de consultation (automesure et mesure ambulatoire de pression sur 24 heures). Elles ont voulu aussi simplifier les cibles de PA à viser qui apparaissent beaucoup moins exigeantes qu’auparavant. Chez les patients âgés, les cibles sont différentes de celles des patients plus jeunes et l’initiation du traitement est d’ailleurs moins rapide. Les bêtabloquants ont été réhabilités dans la stratégie de traitement possible lorsqu’on initie un médicament en présence d’une hypertension artérielle considérée comme nécessitant un médicament antihypertenseur et enfin une stratégie un peu plus claire a été proposée pour l’hypertension artérielle résistante. [less ▲]

Detailed reference viewed: 47 (0 ULg)
Full Text
See detailL'hypertension artérielle
Krzesinski, Jean-Marie ULg

Conference (2014, May 08)

Detailed reference viewed: 63 (1 ULg)
Full Text
Peer Reviewed
See detailCinacalcet treatment at the time of transplantation is associated with a significant risk of delayed graft function in kidney transplant recipients
Jouret, François ULg; WEEKERS, Laurent ULg; GROSCH, Stéphanie ULg et al

in Transplant International (2014, May), 27(S1), 167

The calcium-sensing receptor (CaSR) has been implicated in the ischemia/ reperfusion (I/R) cascade in heart, liver and brain. Renal I/R occurs at the time of transplantation (Tx), with a deleterious ... [more ▼]

The calcium-sensing receptor (CaSR) has been implicated in the ischemia/ reperfusion (I/R) cascade in heart, liver and brain. Renal I/R occurs at the time of transplantation (Tx), with a deleterious impact on early graft function. Here, we retrospectively investigated if the use of cinacalcet, a CaSR agonist, in kidney transplant recipients (KTR) influences early graft recovery. All KTR from 2007 to 2012 in our Academic Hospital were prospectively included in a database. Patients actively treated with cinacalcet on the day of Tx were retrospectively identified from this database and matched with controls on (i) type of donor (living [LD], deceased after brain or circulatory death [DCD]); (ii) cold ischemic time (CIT) ` 1 h; (iii) residual diuresis (` 500 ml); and (iv) donor age (` 5 years). Delayed graft function (DGF) was defined as dialysis requirement after Tx. Baseline characteristics were compared between groups with student’s t-test or Chi-2 as appropriate. The endpoint was the percentage of DGF in both groups. Among 337 KTR, 36 (10.7%) were treated with cinacalcet at Tx. Control group included 61 patients. Characteristics of patients and donors are summarized in the table. DGF occurred in 42 and 23% of cinacalcet-treated and control groups, respectively (p = 0.05). These retro- spective observations suggest that CaSR activation at the time of Tx impairs early graft recovery. [less ▲]

Detailed reference viewed: 84 (19 ULg)
Full Text
See detailComportements à risque et maladies cardio-vasculaires. Comment infléchir le cours des choses?
Etienne, Anne-Marie ULg; Krzesinski, Jean-Marie ULg; André, Jean-François

Scientific conference (2014, April 01)

«Comportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses ?» Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients ... [more ▼]

«Comportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses ?» Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients, comment améliorer la prévention dans le domaine cardio-vasculaire ? [less ▲]

Detailed reference viewed: 46 (18 ULg)
Full Text
See detailComportements à risques et maladies cardio-vasculaires, comment infléchir le cours des choses?
Krzesinski, Jean-Marie ULg; andre, Jean-François

Conference (2014, April 01)

Entre recommandations, croyances et attitudes des médecins, croyances, attitudes et vécu des patients, comment améliorer la prévention dans le domaine cardio-vasculaire?

Detailed reference viewed: 24 (6 ULg)
Full Text
See detailTraitement antihypertenseur : quelles sont les meilleures associations?
Krzesinski, Jean-Marie ULg

Conference (2014, February 22)

Stratégie du traitement de l’HTA en 2014: toujours basée sur le calcul du risque CV. L’HTA, tueur silencieux, est généralement associée à de nombreux autres facteurs de risque CV. Il faut préciser le ... [more ▼]

Stratégie du traitement de l’HTA en 2014: toujours basée sur le calcul du risque CV. L’HTA, tueur silencieux, est généralement associée à de nombreux autres facteurs de risque CV. Il faut préciser le niveau de risque CV en tenant compte de la valeur de PA et des autres F.R. pour décider le moment et le type de traitement ! [less ▲]

Detailed reference viewed: 35 (1 ULg)
Peer Reviewed
See detailUn cas particulier d'amyloïdose AA
MILICEVIC, Martina ULg; GROSCH, Stéphanie ULg; Krzesinski, Jean-Marie ULg et al

Conference (2014, January 22)

Detailed reference viewed: 17 (5 ULg)
Full Text
Peer Reviewed
See detailDetection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine
DELANAYE, Pierre ULg; CAVALIER, Etienne ULg; Morel, Jérôme et al

in BMC Nephrology (2014), 15(9), 1471-2369

Detailed reference viewed: 23 (8 ULg)
Full Text
Peer Reviewed
See detailCockcroft&Gault and CKD-EPI equations: are these equations concordant to adjust drug dosage?
BOUQUEGNEAU, Antoine ULg; Vidal-Petito, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailAccuracy of Cockcroft&Gault and CKD-EPI equations to estimate glomerular filtration rate in obese population
BOUQUEGNEAU, Antoine ULg; Vidal-Petiot, E; Vrtovsnik, F et al

Poster (2014)

Detailed reference viewed: 10 (2 ULg)
Full Text
Peer Reviewed
See detailCombinaison fixe perindopril-indapamide-amlodipine (Triplixam) pour le traitement de l'hypertension arterielle.
Scheen, André ULg; Lancellotti, Patrizio ULg; Krzesinski, Jean-Marie ULg

in Revue medicale de Liege (2014), 69(10), 565-70

Triplixam is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension: perindopril, an ... [more ▼]

Triplixam is a fixed dose combination of three well known antihypertensive agents, with complementary activities, to control blood pressure in patients with arterial hypertension: perindopril, an angiotensin converting enzyme inhibitor, indapamide, a diuretic whith thiazide-like effects but also specific properties, and amlodipine, a long-acting calcium antagonist of the dihydropyridine family. The potential synergic action allows better control of blood pressure with once daily administration, while limiting the incidence of adverse events. Various presentations with different dosages are available to facilitate individualized therapy. Warnings and precautions for use of every molecule should of course be respected. Such a fixed dose combination should contribute to limit clinical inertia and to improve therapeutic compliance. [less ▲]

Detailed reference viewed: 41 (0 ULg)
Full Text
Peer Reviewed
See detailPlace de l'AMP-activated protein kinase dans le preconditionnement ischemique renal.
Erpicum, Pauline; Krzesinski, Jean-Marie ULg; Jouret, François ULg

in Nephrologie & therapeutique (2014)

Kidney transplantation represents the best treatment of end-stage renal disease. In addition to the degree of human leukocyte antigen matching, long-term graft survival is influenced by the quality of the ... [more ▼]

Kidney transplantation represents the best treatment of end-stage renal disease. In addition to the degree of human leukocyte antigen matching, long-term graft survival is influenced by the quality of the graft before its transplantation. Quality criteria include the level of ischemic damage caused by the transplantation per se. Renal ischemic preconditioning (IP) consists of different approaches to prevent ischemia/reperfusion (I/R) damage induced by the interruption and recovery of renal circulation, as observed during transplantation. Distinct animal models show promising results regarding the efficiency of PCI to preserve kidney structure and function in I/R conditions. Characterizing the cellular cascades involved in I/R led to the identification of putative targets of renal IP, including the adenosine monophosphate-activated protein kinase (AMPK). AMPK is a ubiquitous energy sensor, which has been implicated in the maintenance of epithelial cell polarization under energy deprivation. Among others, the anti-diabetic drug, metformin, is a potent activator of AMPK. Here, we summarize the in vitro and in vivo data about the role of AMPK in renal IP. Defining the pharmacological conditions of IP would help to improve the quality of the renal graft before its transplantation, thereby increasing its long-term survival. [less ▲]

Detailed reference viewed: 62 (19 ULg)
Full Text
Peer Reviewed
See detailMesenchymal stromal cell therapy in conditions of renal ischaemia/reperfusion.
Erpicum, Pauline ULg; DETRY, Olivier ULg; WEEKERS, Laurent ULg et al

in Nephrology Dialysis Transplantation (2014), 29

Acute kidney injury (AKI) represents a worldwide public health issue of increasing incidence, with a significant morbi-mortality. AKI treatment mostly relies on supportive manoeuvres in the absence of ... [more ▼]

Acute kidney injury (AKI) represents a worldwide public health issue of increasing incidence, with a significant morbi-mortality. AKI treatment mostly relies on supportive manoeuvres in the absence of specific target-oriented therapy. The pathophysiology of AKI commonly involves ischaemia/reperfusion (I/R) events, which cause both immune and metabolic consequences in renal tissue. Similarly, at the time of kidney transplantation (KT), I/R is an unavoidable event which contributes to early graft dysfunction and enhanced graft immunogenicity. Mesenchymal stromal cells (MSCs) represent a heterogeneous population of adult, fibroblast-like multi-potent cells characterized by their ability to differentiate into tissues of mesodermal lineages. Because MSC have demonstrated immunomodulatory, anti-inflammatory and tissue repair properties, MSC administration at the time of I/R and/or at later times has been hypothesized to attenuate AKI severity and to accelerate the regeneration process. Furthermore, MSC in KT could help prevent both I/R injury and acute rejection, thereby increasing graft function and survival. In this review, summarizing the encouraging observations in animal models and in pilot clinical trials, we outline the benefit of MSC therapy in AKI and KT, and envisage their putative role in renal ischaemic conditioning. [less ▲]

Detailed reference viewed: 72 (37 ULg)
Full Text
Peer Reviewed
See detailClinical and biological determinants of sclerostin plasma concentration in hemodialysis patients
DELANAYE, Pierre ULg; KRZESINSKI, Jean-Marie ULg; Warling, Xavier et al

in Nephron. Clinical Practice (2014), 128

Background: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological ... [more ▼]

Background: Sclerostin is a potent inhibitor of bone formation, but the meaning of its serum levels remains undetermined. We evaluated the association between sclerostin levels and clinical or biological data in hemodialyzed patients (HD), notably parathormone (PTH), biomarkers of bone turnover, vascular calcifications and mortality after 2 years. Methods: 164 HD patients were included in this observational study. The calcification score was assessed with the Kauppila method. Patients were followed for 2 years. Results: Median sclerostin levels were significantly (p < 0.0001) higher in HD versus healthy subjects (n = 94) (1,375 vs. 565 pg/ml, respectively). In univariate analysis a significant association (p < 0.05) was found between sclerostin and age, height, dialysis vintage, albumin, troponin, homocysteine, PTH, C-terminal telopeptide of collagen type I, bone-specific alkaline phosphatase and osteoprotegerin, but not with the calcification score. In a multivariate model, the association remained with age, height, dialysis vintage, troponin, homocysteine, phosphate, PTH, but also with vascular calcifications. Association was positive for all variables, except PTH and vascular calcifications. The baseline sclerostin concentration was not different in survivors and non-survivors. Conclusions: We confirm a higher concentration of sclerostin in HD patients, a positive association with age and a negative association with PTH. A positive association with phosphate, homocysteine and troponin calls for additional research. The clinical interest of sclerostin to assess vascular calcifications in HD is limited and no association was found between sclerostin and mortality. [less ▲]

Detailed reference viewed: 39 (21 ULg)